A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
Related Posts
Low YS, Jackson ML, Hyde RJ, Brown RE, Sanghavi NM, Baldwin JD, Pike CW, Muralidharan J, Hui G, Alexander N, Hassan H, Nene RV, Pike[...]
Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller[...]
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to[...]